Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04029116 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)
A Phase 3 study, sponsored by Scynexis.
- Completed
- Registry status
- Phase 3
- Development phase
- 440
- Enrollment target
NCT04029116 is a Phase 3 study that has completed, run by Scynexis. The registered enrollment target is 440 participants.
The verdict
NCT04029116, a Phase 3 study, has completed, sponsored by Scynexis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 440 participants
- Enrollment target
Study Summary
This study is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral ibrexafungerp (formerly "SCY-078") compared to placebo in female subjects 12 years and older with recurrent VVC (RVVC).
Interventions
- DRUG Placebo oral tablet
- DRUG Fluconazole Tablet
- DRUG IBREXAFUNGERP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 440 participants |
| Start Date | 2019-10-21 |
| Est. Completion | 2021-11-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04029116
The ClinicalTrials.gov registry entry for NCT04029116 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 440 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Scynexis, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo oral tablet is the first listed.
NCT04029116 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04029116 about?
NCT04029116 is a clinical study titled "Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)". This study is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral ibrexafungerp (formerly "SCY-078") compared to placebo in female subjects 12 years and older with recurrent VVC (RVVC).
What is the current status of trial NCT04029116?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 440 participants. The study started on 2019-10-21. Estimated completion is 2021-11-29.
What interventions are being tested in trial NCT04029116?
The interventions under investigation include: Placebo oral tablet (DRUG), Fluconazole Tablet (DRUG), IBREXAFUNGERP (DRUG).
Who is sponsoring clinical trial NCT04029116?
This trial is sponsored by Scynexis, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.